FY2018 EPS Estimates for Catalent Inc Lifted by William Blair (CTLT)
Catalent Inc (NYSE:CTLT) – Stock analysts at William Blair upped their FY2018 earnings estimates for Catalent in a research note issued on Tuesday. William Blair analyst J. Kreger now expects that the company will post earnings per share of $1.53 for the year, up from their prior forecast of $1.52.
Catalent (NYSE:CTLT) last posted its quarterly earnings results on Monday, February 5th. The company reported $0.41 EPS for the quarter, beating the consensus estimate of $0.31 by $0.10. The business had revenue of $606.30 million during the quarter, compared to analysts’ expectations of $565.05 million. Catalent had a return on equity of 23.85% and a net margin of 3.03%. The company’s quarterly revenue was up 25.3% compared to the same quarter last year. During the same period last year, the firm earned $0.27 EPS.
Catalent (CTLT) traded down $0.11 on Thursday, hitting $40.47. The stock had a trading volume of 1,298,233 shares, compared to its average volume of 1,020,925. The company has a quick ratio of 2.49, a current ratio of 2.22 and a debt-to-equity ratio of 2.66. The firm has a market cap of $5,410.07, a PE ratio of 71.00, a P/E/G ratio of 2.33 and a beta of 1.47. Catalent has a 1-year low of $27.48 and a 1-year high of $47.87.
In other news, Director Uwe Roehrhoff acquired 7,500 shares of Catalent stock in a transaction that occurred on Tuesday, November 21st. The stock was purchased at an average cost of $39.22 per share, with a total value of $294,150.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider John R. Chiminski sold 181,458 shares of Catalent stock in a transaction on Tuesday, December 12th. The stock was sold at an average price of $39.62, for a total value of $7,189,365.96. The disclosure for this sale can be found here. Insiders own 1.70% of the company’s stock.
A number of hedge funds have recently modified their holdings of the stock. American Century Companies Inc. raised its holdings in shares of Catalent by 755.3% in the fourth quarter. American Century Companies Inc. now owns 2,631,643 shares of the company’s stock worth $108,108,000 after acquiring an additional 2,323,971 shares during the last quarter. Eagle Asset Management Inc. raised its holdings in shares of Catalent by 290.9% in the third quarter. Eagle Asset Management Inc. now owns 1,153,710 shares of the company’s stock worth $47,636,000 after acquiring an additional 858,600 shares during the last quarter. Emerald Advisers Inc. PA raised its holdings in shares of Catalent by 1,072.2% in the third quarter. Emerald Advisers Inc. PA now owns 604,207 shares of the company’s stock worth $24,120,000 after acquiring an additional 552,663 shares during the last quarter. Emerald Mutual Fund Advisers Trust acquired a new position in shares of Catalent in the third quarter worth $18,420,000. Finally, State Street Corp raised its holdings in shares of Catalent by 10.7% in the second quarter. State Street Corp now owns 4,315,841 shares of the company’s stock worth $151,488,000 after acquiring an additional 418,196 shares during the last quarter. 98.86% of the stock is owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION NOTICE: This piece was originally published by Daily Political and is the sole property of of Daily Political. If you are accessing this piece on another publication, it was illegally stolen and republished in violation of U.S. & international copyright & trademark legislation. The correct version of this piece can be viewed at https://www.dailypolitical.com/2018/02/10/fy2018-eps-estimates-for-catalent-inc-lifted-by-william-blair-ctlt.html.
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. Its segments include Softgel Technologies, Drug Delivery Solutions and Clinical Supply Services. The Softgel Technologies segment is engaged in the formulation, development and manufacturing of prescription and consumer health soft capsules or softgels.
Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.